

SK-MEL-5 | 300157

Description

Organism

Tissue

Disease

Metastatic site

Applications ; ; ; ;MAPK/ERK ; ; ;NK T ()

Synonyms SK-Mel-5, SK MEL 5, SK.MEL.5, SK-MEL5, SK 5, SK 5, SK 5, SK 5, AA-Mel

Age 24

Gender

Ethnicity

Morphology Stellate

Cell type /

Growth properties

Citation SK-MEL-5(300157)

Biosafety level 1

NCBI_TaxID 9606

CellosaurusAccession CVCL_0527

SK-MEL-5 | 300157

GMO Status , T. Takahashi .

Protein expression P53

Isoenzymes PGM1, 1-2, PGM3, 1, ES-D, 1, AK-1, 1, GLO-1, 1-2, G6PD, B, : 0.0860

Tumorigenic ,

Products

Culture Medium EMEM(MEM), w: 2mM L- , w: 2.2g/L NaHCO₃, w: EBSS(820100a)

Supplements 10% FBS 1% NEAA

Dissociation Reagent

Doubling time 24~36

Subculturing PBS . T25 3~5ml, T75 5~10ml PBS . T25

Split ratio 1~3

Seeding density $1 \times 10^4 / \text{cm}^2$

Fluid renewal 2~3

Post-Thaw Recovery 5×10^4 , 24 .

Freeze medium (FBS) + 10% DMSO , CM-1(Cytion 800100)

SK-MEL-5 | 300157

Thawing and Culturing Cells	
1.	.
2.	-150°C , 3 .
3.	37°C 40~60 .
4.	, 70% .
5.	8ml 15ml .
6.	300 x g 3 .
7.	10ml . T25 , T25
8.	.

Incubation Atmosphere 37°C, 5% CO₂ .

Flask Coating

Freezing Procedure -78°C .

Shipping Conditions -78°C .

Storage Conditions -150°C -196°C .80°C .

/ / HLA

Sterility PCR .

SK-MEL-5 | 300157

STR

- Amelogenin:** x,x
- CSF1PO:** 10,13
- D13S317:** 10, 12
- D16S539:** 10, 12
- D5S818:** 11,13
- D7S820:** 9,12
- TH01:** 6,9
- TPOX:** 11
- vWA:** 14,18
- D3S1358:** 16, 17
- D21S11:** 29
- D18S51:** 15, 16
- Penta E:** 5,12
- Penta D:** 9,11
- D8S1179:** 12 15
- FGA:** 20,2,22

HLA

- A*:** '02:01:01, '11:01:01
- B*:** '07:02:01, '40:01:02
- C*:** '03:04:01, '07:02:01
- DRB1*:** '04:01:01, '13:01:01
- DQA1*:** '01:03:01, '03:01:01
- DQB1*:** '03:02:01, '06:03:01
- DPB1*:** '03:01:01, '16:01:01
- E:** '01:01, '01:03